Iodine
Dietary SupplementIn intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.
NCT Number: NCT06721273
Iodine has been identified as a potential factor influencing female fertility during the childbearing years. The American Thyroid Association recommends that women attempting to conceive take a supplement containing 150 µg of iodine. However, no clinical trials have specifically examined the necessity of iodine supplementation in women experiencing infertility. Furthermore, no information is available on the optimal dose and duration of iodine supplementation to increase the chances of successful treatment in this group of women. Therefore, this study aims to investigate the effects of iodine supplementation on fertility parameters in infertile women.
Trial opening soon.
Get Notified18 year–45 year
Female
Interventional
Not applicable
This double-blind randomized clinical trial will be conducted in infertility clinic on women with diminished ovarian reserve and undergoing in vitro fertilization (IVF) cycle treatment. According to the Bologna criteria, decreased ovarian reserve is defined as having 3 to 5 antral follicles and an anti-Müllerian hormone concentration ranging from 0.1 to 1.5 ng/ml. All women diagnosed with diminished ovarian reserve who meet the inclusion and exclusion criteria outlined in the general information section of the clinical trial and have provided written consent to participate will be examined. Following enrollment and baseline measurements, women will be randomly assigned to treatment groups-placebo and iodine supplement (150 µg/day of iodine)-in a 1:1 allocation ratio, using a random number table. In the intervention group, women will take 150 µg of iodine daily (one tablet per day, Tavan Institute, Tehran, Iran) for two months prior to starting the new IVF cycle. In the control group, participants will take a placebo tablet daily (containing white wheat flour, designed to match the size, shape, and color of the iodine tablet, Tavan Institute, Tehran, Iran) for the same duration before beginning the new IVF cycle. Women of two groups will be followed until the end of IVF cycle. Women in both groups will be monitored until the completion of the IVF cycle. Throughout the study, the following parameters will be assessed based on the timeline of the IVF cycle: the number of retrieved oocytes, the number of mature (MII) oocytes, the number of embryos, embryo quality, biochemical pregnancy, and clinical pregnancy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.
Women will take a placebo tablet daily (containing white wheat flour, which is similar to iodine table in terms of size, shape, and color, Tavan Institute, Tehran, Iran) 2 months before starting the new IVF cycle.
Time frame: 2 weeks after the start of ovarian stimulation (approximately 2 months after intervention)
Total count of mature eggs (oocytes) collected from a woman's ovaries during an IVF cycle through the egg retrieval procedure by embryologists
Time frame: 2 weeks after the start of ovarian stimulation (approximately 2 months after intervention)
Total count of oocytes that have reached the metaphase II stage of meiosis. This measurement is done by embryologists
Time frame: 16-18 hours after insemination
Number of fertilized eggs (oocytes) that develop into embryos after the fertilization process with sperm
Time frame: 3 days after fertilization
Quality of embryos is graded by embryologists using 3-point score scale
Time frame: 12 days after embryo transfer
Biochemical pregnancy is confirmed by βHCG test
Time frame: 3 weeks after embryo transfer
Presence of one or more gestational sacs during transvaginal scans
Contact information is provided by the study sponsor or research team.
Tehran University of Medical Sciences
Other
The Effect of Iodine Supplementation on Fertility Parameters in Women Experiencing Infertility
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07736261
Genital Diseases, Infertility
Banhā, Qalyubia Governorate, Egypt
View Trial DetailsNCT07700602
Clinical Pregnancy After Single Embryo Transfer, Embryo Diagnosis and Selection
Ho Chi Minh City, Vietnam
View Trial DetailsNCT07569302
Genital Diseases, Infertility
Giza, Giza Governorate, Egypt
View Trial DetailsNCT07461077
Advanced Age, Embryo Quality
Guangzhou, Guangdong, China
View Trial Details